ClinicalTrials.gg
RecruitingNCT05560659POPSTAR IIUpdated Nov 9, 2026

Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy

A Phase 2 interventional study of 177Lu-PSMA in Oligometastatic Prostate Cancer, sponsored by Peter MacCallum Cancer Centre, Australia. Recruiting at 4 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Peter MacCallum Cancer Centre, Australia · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.
Updated Nov 9, 2026Primary completion movedStudy contact changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Prostatic Neoplasms by Peter MacCallum Cancer Centre, Australia — 2 open to participants now, 9 under way, 1 of them phase 3. Prostatic Neoplasms · Peter MacCallum Cancer Centre, Australia.

Planned enrollment
5th of 13
92 · median 66
Started
2023
the only one that year
Phase 2
2 of 14
1 open now
Registered
9th of 14
by date

Among the 14 studies in Prostatic Neoplasms by Peter MacCallum Cancer Centre, Australia, this one is the 5th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 2, and was the 9th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

2 of the 14 studies in Prostatic Neoplasms by Peter MacCallum Cancer Centre, Australia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Prostatic Neoplasms by Peter MacCallum Cancer Centre, Australia, or all of them as a file.
02

Study summary

The aim of this study is to assess the progression free survival (PFS) of SABR alone and SABR + 177Lu-prostate-specific membrane antigen (PSMA) in patients with oligometastatic prostate cancer undergoing PSMA positron emission tomography (PET) staging.

Read the detailed description

Metastatic disease in patients involves treatment including systemic chemotherapy, hormonal therapy and androgen deprivation therapy. "Oligometastases" was termed to describe a state of metastatic transition wherein the cancer cells travel from the original site of tumour to other parts of the body and form fewer number of tumours. Sustained systemic therapies such as chemotherapy have been used as the Standard of care (SOC) in most cases. Novel radiotherapy like Lutetium-177 PSMA radionuclide therapy have been explored in earlier disease settings to further improve outcomes. Based on evidence from few previous trials and emerging safety data from ongoing trials, it is an effective addition to SOC to further improve patient outcomes.

The detection of prostate cancer can be done by a highly sensitive and specific test using the PSMA-PET small molecules. The evidence of high uptake of these PSMA-PET small molecules assists in selection of patients potentially suitable for novel PSMA targeted radionuclide therapy. Previous studies have demonstrated novel molecular imaging techniques, particularly PSMA PET/CT in the biochemical recurrence setting is leading to an increasing number of patients being diagnosed with oligometastatic disease which would not have been detected using conventional imaging techniques.

The Stereotactic ablative body radiotherapy (SABR) is also an emerging localised treatment option for oligometastatic prostate cancer. It delivers a highly focused beam of external radiation concentrated over a tumour and has been used to treat low volume metastatic disease to delay the use of systemic therapies. Results from previous studies show that it a safe, well-tolerated and progressively used in real-world clinical practice to treat patients with low volume of metastatic cancer. Based on the results of a previous trial done by this team, patients with one to three sites of disease treated with a single session of SABR showed promising outcomes.

The aim of this trial is to evaluate the progression free survival of SABR alone and SABR + 177Lu-prostate-specific membrane antigen (PSMA) in patients with oligometastatic prostate cancer undergoing PSMA positron emission tomography (PET) staging.

92 men with oligometastatic prostate cancer will be enrolled in this trial and split into 1:1 ratio to either stereotactic ablative body radiotherapy (SABR) alone or SABR plus 2 cycles of 177Lu-PSMA over a period of 24 months.

03

Conditions studied

  • Oligometastatic Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male aged 18 years or older at screening
  2. Patient has provided written
  3. confirmed prostate adenocarcinoma w
  4. Prior definitive treatment of the primary with either curative intent radiotherapy and/or surgery
  5. Patient has 1-5 sites of nodal or bony on 68Ga-PSMA or 18F-DCFPyL PET/CT
  6. Adequate haematological function as defined by:

    • (ANC) ≥1.5 x 109/L
    • count >150x 109/L
    • ≥100 g/L
    • ≥ 40mL/min (Cockcroft-Gault formula)
  7. Assessed as suitable for SABR by a radiation oncologist
  8. Patients must agree to use an adequate method of
  9. Have a performance status of 0-1 on the Performance Scale

Exclusion criteria

Exclusion Criteria:

  1. Prior systemic therapy for prostate cancer. Prior ADT is allowed but ADT within 6 months of screening for the study is not allowed. If patients have received prior ADT, serum testosterone levels must be above the lower limit of normal
  2. Any visceral (AJCCC M1c) metastases
  3. Symptomatic cord compression, or clinical or imaging findings concerning for impending cord compression
  4. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator
  5. Has a known additional that is progressing or required active treatment in the last 2 years Note: Basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer or carcinoma in situ such as breast cancer in situ that has undergone potentially curative therapy are not excluded.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
92 participants (estimated)

Study arms

  • No intervention
    Stereotactic ablative body radiotherapy (SABR) alone

    1-3 fractions of SABR to all sites of disease

  • Experimental
    SABR plus 2 cycles of 177Lu-PSMA

    cycles of 177Lu-PSMA with 1-3 fractions of SABR to all sites of disease between cycle 1 and 2

    Drug: 177Lu-PSMA

Interventions

  • Drug177Lu-PSMA

    Lutetium-177 (177Lu)-PSMA is a radiopharmaceutical comprised of a small molecule inhibitor of PSMA that binds with high affinity to PSMA, labelled with 177Lu. 177Lu has favourable characteristics for radionuclide therapy emitting both a short-range (1-2mm) cytotoxic beta-particle, minimising irradiation of non-targeted normal tissues, alongside gamma emission that allows imaging. Numerous retrospective series initially demonstrated high clinical activity and limited normal tissue toxicity using PSMA-617 and PSMA-I\&T, which are the most advanced small molecule inhibitors of PSMA, radiolabelled with 177Lu

06

What researchers measure

Primary outcomes

  1. Evaluate the (bPFS) of SABR alone and SABR + 177Lu-PSMA

    The biochemical progression free survival (bPFS) of SABR alone and SABR + 177Lu-prostate-specific membrane antigen (PSMA) in patients with oligometastatic prostate cancer undergoing PSMA positron emission tomography (PET) staging.

    Time frame: Through study completion, up until 12 months after the last patient commences treatment

Secondary outcomes

  1. The AEs according to CTCAE v5.0

    The type, grade and relationship to treatment of AEs will be assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 5.0

    Time frame: Through study completion, up until 4 months ± 10 days from the commencement of ADT following progression

  2. The PSA-response rate

    PSA response will be defined as a 50% or greater decrease in PSA from baseline to the lowest post-baseline PSA result

    Time frame: Through study completion, up until time of biochemical progression +/- 10 days

  3. The ADT-free survival

    ADT-FS is defined as the time from randomisation to the date of initiation of androgen deprivation therapy or date of death due to any cause

    Time frame: Through study completion, up until biochemical progression +/- 10 days

  4. The pattern of recurrence on PSMA PET

    Pattern of relapse will be evaluated on the PSMA PET at progression in relation to baseline PSMA PET, including: a) number of new sites of disease; b) location of new disease of disease (pelvic nodes, extra-pelvic nodes, bone, viscera); c) progression at prior sites (yes or no)

    Time frame: Time of biochemical progression +/-10 days

  5. The patient reported quality of life

    QoL will be assessed using the EORTC QLQC-30 and EQ-5D-5L questionnaires

    Time frame: From the date of randomisation to the date of progression

  6. The MDT PFS

    MDT PFS is defined as the time from first MDT after initial treatment to first documented subsequent disease progression (biochemical, or clinical using the same definition as the primary endpoint) or date of death, whichever comes first. Only patients who received MDT as the only treatment modality after initial treatment will be included.

    Time frame: Time point after Cycle 2 (28 days follow up post Cycle 2) until biochemical progression

  7. The overall survival

    OS is defined as the time from randomisation to the date of death from any cause

    Time frame: Time point post randomisation to the date of death from any cause

  8. Healthcare costs associated with delivering the intervention and management of AEs

    Health economic analysis is planned to assess the real-world cost-effectiveness and broader economic impact of using 177Lu-PSMA + SABR compared to SABR alone (if an effect is observed). Costs included in the analysis will focus on those relevant to the intervention (177Lu-PSMA) including treatment-related hospitalisations, clinic visits, PSMA PET scans, and associated medical service utilisation. Additionally, healthcare resource used and their associated costs including those associated with the complications arising from each study arm will be extracted from hospital administrative records and data collected during the trial (e.g., CTCAE v 5.0 Toxicity Record) and compared to provide an understanding of overall costs.

    Time frame: Through study completion, an average of 3 years

  9. The PET-PFS

    PET-PFS is defined as the time from randomisation to the date of radiological progression on PSMA PET/CT scan or death due to any cause, whichever comes first. Patients alive without a rise in PSA will be censored at last PSA assessment

    Time frame: Through study completion, from the date of randomisation to the date of radiological progression or death from any cause, whichever comes first.

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual requests for data sharing must be accompanied by ethical approval and will be considered at request

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Nov 2026, 35 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 35 months is below that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

Primary completion moved once since we started tracking on Sep 25, 2026: May 2026 → Nov 2026, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2022
First posted
Sep 29, 2022
StartActual
Dec 14, 2023
Primary completionEst.
Nov 2026was May 2026
CompletionEst.
May 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Icon Cancer Centre · Melbourne, Australia
Nov 9, 2026
Primary completion
May 2026→Nov 2026
Nov 9, 2026
Contact
Study contact changed: G•••@petermac.org · •••6830→h•••@petermac.org · •••8566. See the current contact
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    1 site added
    Show site
    • Icon Cancer Centre · Melbourne, Australia
    Primary completion May 2026→Nov 2026
    Contact Study contact changed: G•••@petermac.org · •••6830→h•••@petermac.org · •••8566. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05560659
Lead sponsor
Peter MacCallum Cancer Centre, Australia
Responsible party
Sponsor
First posted
Sep 29, 2022
Start date
Dec 14, 2023
Primary completion
Nov 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Haris Ahmad
Contact
haris.ahmad@petermac.org
+61 3 8559 8566
Annette VanDerHeyden
Contact
Annette.VanDerHeyden@petermac.org
+61488048792
A/Prof. Shankar Siva
principal investigator · Peter MacCallum Cancer Centre, Australia
Dr Sidney Levy
principal investigator · Peter MacCallum Cancer Centre, Australia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion